IMPORTANCE Salvage chemotherapy for recurrent chest wall lesions in breast cancer results in response rates of 20% to 30%. Preclinical studies showed significant disease regression could be induced in murine chest wall mammary cancers with a topical toll-like receptor (TLR)-7 agonist, imiquimod.
T herapies for recurrent breast cancer chest wall disease are not curative and have low response rates. Studies in mammary tumors of transgenic mice demonstrate that topical toll-like receptor (TLR)-7 agonist, imiquimod stimulates type 1 cytokine secretion, up-regulates immune costimulatory molecules in the tumor, and results in inhibition of cancer growth. 1 Taxanes also have immunomodulatory effects, increased interferon-γ production by antigen presenting cells, and enhanced natural killer (NK)-cell activity. 2 Patients with breast cancer often demonstrate NK dysfunction and tumor antigen presenting cells promote type 2 cytokine secretion, dampening the development of cytotoxic T cells. 3, 4 Combination therapies that enhance interferon (IFN)-γ secretion may reverse established immune suppression. We examined whether the combination of topical imiquimod and weekly intravenous albumin-bound paclitaxel (nab-paclitaxel) could induce clinical responses in patients with treatment-refractory chest wall disease.
Methods

Participants
A targeted accrual of 15 patients with stage IV disease were enrolled from 2009-2012 after written informed consent was obtained. Institutional review board approval was granted by the University of Washington Cancer Consortium. Eligibility included treatment refractory progressive disease and measurable chest wall or cutaneous metastasis. Concurrent bisphosphonate, HER2-targeted, and endocrine therapies were allowed. Fourteen age-matched donor control blood samples were also analyzed. Participants were not compensated for their participation. The trial protocol is included in Supplement 1.
Study Design
We report a phase 2 single-arm study (eFigure 1 in Supplement 2). The objectives were safety and objective response rate (ORR). An ORR of 50% or higher or complete response (CR) rate of 10% or higher were benchmarks based on historical ORR with salvage chemotherapy of 30% and CRof less than 2%. [5] [6] [7] [8] Fifteen patients was statistically sufficient for 80% confidence that the ORR was within 0.16 of the true response rate. Toxic effects were evaluated by Common Terminology Criteria for Adverse Events, version 3.0. Target lesion(s) were assessed by modified World Health Organization criteria with response defined as the change in target lesion size over 13 weeks.
Tumor Analysis
Skin biopsy samples were obtained at baseline and week 13 and stained for CD3, CD4, CD8, CD25 and Forkhead box protein (FOXP)3. 9 For each case, 3 high-powered fields (hpf) (original magnification × 40), representative of prominent areas of lymphocytic infiltrates, were scored. The total number of lymphocytes and other cells in the 3 hpfs were counted and reported as mean number of cells per hpf.
Flow Cytometry
The data are expressed as percentage PD- 10 
Statistical Analysis
Statistical analysis included a 2-tailed t test using GraphPad statistical software (version 7.01, GraphPad Software Inc). A P value less than .05 was considered statistically significant.
Results
Combination Chemoimmunotherapy
The median age at baseline of study participants was 54 years (range, 46-92 years). All patients had a chest wall malignant abnormality documented by skin biopsy. Eighty percent of patients were hormone receptor negative and had received 4 or more previous chemotherapies (eTable 1 in Supplement 2). Nine patients (60%) completed all treatment cycles, 3 (20%) completed 2 cycles, and 2 (13%) completed 1 cycle. Of 358 toxic effects 330 (92%) were grades 1 or 2, and 27 (8%) were grade 3 (eTable 2 in Supplement 2). Three patients required nab-paclitaxel dose reduction of 20% for grade 3 neutropenia or neuropathy. There were no treatment discontinuations owing to toxic effects. ing no evidence of tumor but increased inflammatory infiltrate. Three patients had stable disease (SD) and 1 had progressive disease. The ORR was 10 of 14 (72%). Responses were not associated with tumor size (eTable 3 and eFigure 3 in Supplement 2). Intratumoral T-cell infiltrates were present in all at baseline and varied from a sparse infiltrate (<7 CD3 + cells per hpf) to strong infiltration (66 CD3 + cells per hpf), but failed to show consistent trends pretreatment to posttreatment. The median duration of response after therapy was 12 weeks (range, 4-25 weeks) in patients with CR, 16 weeks (range, 4-28 weeks) in PR patients, and 3 weeks (range, 1-4 weeks) in SD patients.
Patient Response to Combination Chemoimmunotherapy
Factors Associated With Suboptimal Clinical Response
Patients had significantly elevated levels of PD-1 + CD4 + peripheral blood T cells (mean, 6.6%; range, 2.4%-12.0%) compared with controls (mean, 3.1%; range, 1.1%-5.5%; 95% CI, 1.8-5.8; P < .001) ( Figure 2A) . Similarly, PD-1 + CD8 + T cells were significantly elevated (mean, 7.1%; range, 2.5%-21.0%) compared with controls (mean, 4.1%; range, 0.9%-8.4%; 95% CI, 0.2%-7.1%; P =.04) ( Figure 2B ). Figure 2C ) and PD-1
2.8%-21%; 95% CI, 1.8%-8.4%; P = .01) ( Figure 2D ). There was no difference in NK or B cells between groups. Although breast cancer patients had elevated monocytes compared with controls (95% CI, 12.1-34.0; P = .002), these were not predictive of outcome. The mean pretreatment mMDSC level was 6.4% (range 0.9%-22.0%) in patients and 0.9% (range 0.0%-4.0%) in controls, (95% CI, 1.5%-9.4%; P < .01) ( Figure 3A) . The mean level of regulatory T (Treg) cells pretreatment was 4.6% (range, 1.2%-9.8%) compared with 2.1% (0.8%-4.6%) in controls, (95% CI, 1.2%-3.8%; P < .001) ( Figure 3B ). mMDSC levels were predictive of suboptimal response with patients not achieving a CR having elevated levels; mean, 9.1% (range, 2.3%-22.0%) significantly higher than controls (95% CI, 3.6%-12.7%; P = .001); whereas mMDSC levels in patients with CR were similar to donors; mean 3.1% (range, 0.9%-9.8%; P = .056) Figure 3C ). The Treg level was elevated in both complete (95% CI, 0.5-3.6; P = .01) and suboptimal responders (95% CI, 1.3-4.2; P < .001) compared with controls ( Figure 3D ).
Discussion
In breast cancer, robust T-cell infiltrates have been associated with superior response rates to chemotherapy and increased progression free and overall survival. 11 Most patients with breast cancer, however, have no to low levels of tumor infiltrating T cells (TIL Combination immunotherapy for treatment of refractory chest wall lesions demonstrates a response rate higher than that reported for conventional chemotherapy. The addition of a PD-1 or PD-L1 directed monoclonal antibody to this combination regimen and a longer course of treatment could significantly improve response duration and potentially affect concurrent systemic disease.
Conclusions
Chemoimmunotherapy is an active regimen with low toxic effects. Inhibition of specific mechanisms of immune suppression, PD-1 up-regulation and mMDSC, could enhance efficacy and provide a new treatment approach to patients with refractory breast cancer in the chest wall.
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Rationale
Breast cancer cutaneous lesions can present either as a local chest wall recurrence or as an isolated site of metastatic disease and occur in up to 30% of breast cancer patients. The treatment of recurrent chest wall disease is difficult and full thickness chest wall resection, a common therapeutic approach, is disfiguring, not curative and associated with significant morbidity. Salvage chemotherapy used in the second-and third-line setting results in overall response rates of 20-30%, at best. [1] [2] [3] [4] [5] Thus, the treatment of cutaneous lesions whether locoregional or a distant metastasis remains a challenge, and further investigation of novel treatment strategies is warranted.
Imiquimod, a small molecule immune response modifier that can be applied topically, generates an immune signal similar to that of pathogenic bacteria, triggering immune activation via toll-like receptor ligand (TLR)-7. Pre-clinical studies have shown imiquimod to stimulate the secretion of cytokines, up-regulate immune co-stimulatory molecules, and augment immunity to tumor antigens. 6 Imiquimod has clinical activity against a variety of cutaneous malignancies including case-reports of responses in breast cancer cutaneous metastasis. [7] [8] [9] Conventional chemotherapy, such as paclitaxel, a commonly used agent in metastatic breast cancer (MBC), may also modulate immune function. Immunostimulatory effects of paclitaxel include stimulation of IL-12 production, increased serum levels of interferon-gamma (IFN-), and enhanced NK/LAK cell activity. 10, 11 Abraxane, a new taxane formulation, can be administered without the immunosuppressive steroid pre-treatment required with paclitaxel. Abraxane can be used in conjunction with imiquimod without compromising anti-tumor immunity. Moreover, the chemotherapy-associated immunologic effects of Abraxane could potentially synergize and augment the anti-tumor effect of imiquimod. We hypothesize that imiquimod can function to enhance endogenous tumor-specific immunity, allowing the tumor itself to "auto-immunize" the patient, and that the use of topical TLR agonists, like imiquimod, can lead to higher response rates in breast cancer patients with chest wall and cutaneous metastasis when combined with chemotherapy. The purpose of this study is to evaluate the safety and clinical efficacy of imiquimod and Abraxane combination therapy. In addition, we will evaluate if treatment with imiquimod and Abraxane results in development of systemic T cell immunity directed against common breast cancer antigens as well as the development of a tumor microenvironment that would support an adaptive tumor specific immune response. define a treatment cycle and patients will receive a maximum of 3 cycles. The treatment period will last 12 weeks followed by 3 follow-up visits at 4-week intervals.
Objectives
Number of Patients 15 patients will be enrolled.
Outcome Measures
Primary Endpoints: Safety and systemic toxicity will be determined by chemical and clinical parameters evaluated at various time points as described in Section 7. Toxicity grading will be evaluated according to the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 and monitoring of adverse events will be done per FDA and NCI guidelines.
The cutaneous antitumor activity of the approach will be assessed using modified WHO criteria and tumor evaluation will be done at baseline and at 4 week intervals until week 24. All measurable cutaneous lesions will be recorded and measured at baseline and target lesions will be identified and marked using a template. Target lesions will be evaluated by the following response criteria: Complete response (CR), Partial response (PR), Stable disease (SD), or Progressive disease (PD). Additionally, 2-mm skin punch biopsies will be taken from target lesions pre-and post-treatment for assessment of pathologic response.
Secondary Endpoints: Endogenous immunity to common breast cancer antigens will be evaluated using IFN-ELISPOT assay. In patients without pre-existent immune response, the acquisition of a positive immune response (PBMC precursor frequency more robust than 1:20,000) after treatment begins will constitute augmentation. In patients with pre-existent immune response to the tumor antigens, augmentation will have occurred, if the final response to a tumor antigen is greater than 2 times the baseline level.
Serum TGF-levels will be evaluated at baseline, at week 13 (after cycle 3 of imiquimod/Abraxane); and at week 24 (end of study). Analysis of serum will be performed by ELISA. A decrease in serum TGF-levels will be defined as a reduction of at least β5% from baseline value to the value measured at week 24. 12, 13 The treatment of recurrent chest wall disease is difficult, particularly when the chest wall has been previously irradiated. One of the most common therapeutic approaches, full thickness chest wall resection, is not curative, is disfiguring, and is associated with significant morbidity. Skin metastasis occurs in up to 24% of breast cancer patients and are difficult to treat despite systemic chemotherapy. 7, 14 Second-and third-line salvage chemotherapy results in overall response rates of 20-30%, at best. [1] [2] [3] [4] [5] Thus, further investigation of novel treatment strategies are needed.
Small molecule immune response modifiers (IRMs) are chemical compounds that generate an immune signal similar to that of pathogenic bacteria, triggering immune activation via toll-like receptor ligands. This immune signal leads to activation of antigen presenting cells (APC) with the production of various proinflammatory cytokines that have antiviral, anticancer, and immune modulating activities. Imiquimod, a TLR-7 agonist with clinical activity against genital warts and basal cell carcinoma (BCC) may also have activity in the treatment of breast cancer cutaneous metastasis. [7] [8] [9] Preclinical studies in neu-transgenic mice have shown imiquimod to completely stop the growth of breast tumors. 6 Imiquimod stimulated the secretion of cytokines and up-regulated major histocompatibility complex (MHC) molecules on the tumor cell surface and stimulated the influx of cytotoxic T cells into the tumor. Moreover, imiquimod treatment resulted in prolonged upregulation of IFN-in the tumor bed which has been associated with generating a local tumor microenvironment capable of sustaining an adaptive immune response. Additionally, treatment with imiquimod augmented immunity specific to tumor antigens with new antibody and T cell responses developing to rat neu. Conventional chemotherapy, such as paclitaxel, a commonly used agent in MBC, may also modulate immune function. Immunostimulatory effects of paclitaxel include stimulation of IL-12 production by tumor macrophages and decreased tumor macrophage mediated suppression of T-lymphocyte proliferation, increased serum IFN-levels, and enhanced NK/LAK cell activity. 10, 11 Abraxane, a new taxane formulation can be used in conjunction with imiquimod as immunosuppressive steroid pre-treatment is not required. We hypothesize the chemotherapy-associated immunologic effects could potentially synergize and augment the potential anti-tumor effects of imiquimod.
The primary objectives of this study are to: (1) evaluate the safety of chemoimmunotherapy with topical imiquimod and Abraxane in breast cancer patients with recurrent chest wall disease or cutaneous metastasis, and (2) evaluate the antitumor effects of topical imiquimod and Abraxane chemoimmunotherapy in those patients. The secondary objectives are to: (1) examine whether treatment with topical imiquimod and Abraxane chemoimmunotherapy augments endogenous tumor specific immunity and, (2) and assess the effect of chemoimmunotherapy on circulating TGF-levels.
Background
A. Recurrent breast cancer to the chest wall or skin metastasis is difficult to treat. Breast cancer treatment remains particularly challenging especially at advanced stages of the disease. Breast cancer tumor cells appear to be able to escape immunologic responses through complex and variable mechanisms, including self-tolerance to antigens, modification and/or down regulation of MHC molecules, and cytokine production by tumor cells. 15 Thus, immunotherapeutic approaches to treatment may provide a novel mechanism by which to correct some of these defects and potentially augment a tissue destructive immune response. Breast cancer skin lesions present either as local recurrences following mastectomy or breast conserving therapy, or as a site for metastatic disease. Local recurrences typically present as one or more asymptomatic nodules, usually in or near the mastectomy or lumpectomy scar. Most are initially operable and prognosis is influenced by time of recurrence, type of tumor, invasion and previous therapy. Moreover, skin recurrences often do not respond as well to chemotherapy as other soft tissue disease sites. Distant metastatic skin lesions, or cutaneous metastases, may present as isolated lesions or in conjunction with other visceral, soft tissue, or bone metastases. The goal of therapy for metastatic disease is to improve or maintain quality of life and increase survival, however given the limited success of available therapies, treatment is usually palliative. In addition to the general decline in health associated with advanced cancer, visible tumor may pose an additional psychological burden to afflicted patients. 16 Currently, surgery, radiotherapy and chemotherapy represent the mainstay of therapy for breast cancer cutaneous metastases. Salvage chemotherapy used in the second-and third-line setting for the treatment of cutaneous metastases results in overall response rates of 20-30%. [1] [2] [3] [4] [5] Given the high prevalence of breast cancer and the limited success of salvage chemotherapy in the metastatic setting, novel treatments are of key importance.
Protocol 6578/131 B. Breast cancer is immunogenic and augmenting tumor-specific immunity has been shown to have an anti-tumor effect. Patients with breast cancer are able to develop both systemic and local immune responses against their tumor. In recent years it has become clear that breast cancer is an immunogenic tumor and patients can demonstrate immunity at low-levels to a variety of tumor antigens such as HER-2/neu (HER2), CEA, and MAGE-3. [17] [18] [19] [20] Studies performed evaluating immune inflammatory infiltrates in breast tumors have demonstrated local tumor associated lymphocytic infiltrates. Additionally, dense infiltration of breast tumors with immune effector cells such as dendritic cells (DC) and tumor infiltrating lymphocytes (TIL) may be correlated with positive prognostic factors and clinical outcome. 21, 22 Recent studies evaluating novel strategies to augment immunity in breast cancer are demonstrating immune and clinical responses. For example, our group has focused on immunizing breast cancer patients with minimal or non-detectable disease burden with multi-peptide vaccines targeting HER2. [23] [24] [25] Long-term follow-up reveals a significant number (37%) of Stage IV patients are still alive a median of 7 years after receiving their last vaccine.
In more recent work, Avigen and colleagues treated 16 breast cancer patients with breast tumor cell/dendritic cell fusion vaccines and observed tumor regressions in 2 patients and disease stabilizations in another. 26 These clinical responses were accompanied by increased tumor specific T cell precursor frequencies in the peripheral blood of treated patients. It is likely that an impediment to seeing more clinical responses is that patients with breast cancer have elevated levels of regulatory T cells (Tregs) both in the peripheral blood and at the site of tumor. 27 Furthermore, breast cancer patients have been shown to have high levels of transforming growth factor-beta (TGF-) in their serum which has been shown to be linked with a poor prognosis. 28 It has been postulated that the major source of circulating TGF-in cancer patients is by secretion of the cytokine via Tregs. TGF-has been demonstrated to down-regulate MHC molecules on tumor cells and enhance tumor immune evasion, the effects of which can be reversed via IFN-secretion. 29, 30 We hypothesize that strong upregulation of IFN-with imiquimod treatment will down regulate TGF-expression in the tumor and decrease detectable serum levels of the immunosuppressive cytokine. Moreover, the immune modulating properties of imiquimod may result in augmented immunity to tumor antigens allowing the tumor itself to "auto-immunize" the patient. Additionally, we hypothesize that TLR agonists like imiquimod, which have powerful immune properties, administered in combination with chemotherapy such as Abraxane, can lead to a higher incidence of tumor regression in breast cancer patients with cutaneous metastases than those treated with salvage chemotherapy alone.
C. Chemoimmunotherapy can have immunomodulatory effects that may enhance antitumor response and influence clinical outcome. In recent years, the innate immune system has been increasingly recognized to contribute to the control of viral infections and tumors. Pathogen associated molecular patterns have been found to activate the innate immune system through TLRs. There are 10 known TLRs in humans that are preferentially expressed on cells of the innate immune system. 31, 32 Activation of TLRs using bacterial components (BCG, CpG DNA) and viral components (RNA) has also shown antitumor effects in preclinical murine models. Although the mechanism of action that these TLR agonists use to mediate their antitumor effects is largely unknown, it appears that direct activation of the innate immune system is a prerequisite to tumor eradication. Aldara (imiquimod 5% cream), a small molecule IRM activates the innate immune system via TLR-7 which is present on DCs, macrophages, and monocytes. Subsequent activation of these cells lead to release of proinflammatory cytokines including interferon-alpha (IFN-), tumor necrosis factor-alpha (TNF-), IL-1, and IL-12.
33 These cytokines are believed to then drive the activation of the adaptive immune response toward the Th1 cell-mediated pathway. This modulation of immune response, along with creation of an anti-viral state including regulation of NK-cell activity is thought to be critical for control of viruses and tumors. Additionally, topical application of imiquimod has been shown to enhance the maturation and migration of Langerhans cells to regional lymph nodes, thus enhancing antigen presentation to naïve T cells and inducing a more specific immune response. 33 The use of imiquimod for the treatment of cutaneous metastases of breast cancer is supported preclinically in transgenic mice developing spontaneous breast cancer, and in case-reports in which topical application of imiquimod 5% cream elicited complete clinical and histopathological remission of cutaneous breast metastases (and our own unpublished data). 6, 7 While imiquimod may actively modulate a tumor-directed cellular immune response it is unclear if Th1 adaptive immunity has a beneficial effect on clinical outcome. Recent data has shown that increased expression levels of genes related to inflammation, specifically IFN-in colorectal tumors, correlates with favorable prognosis. 34 This observation suggests that time to recurrence and overall survival are influenced, in part, by a tumor environment that will support an adaptive immune response and warrants further investigation. Conventional cytotoxic chemotherapy also modulates immune function. Cyclophosphamide was one of the first cytotoxic drugs to be recognized as having an immune stimulatory effect. Other cancer chemotherapy agents, including taxanes, have been shown to possess immunostimulatory properties. In an immunocompetent murine model, paclitaxel was found Protocol 6578/131 to stimulate IL-12 production by tumor macrophages and to reduce tumor macrophage mediated suppression of Tlymphocyte proliferation. 10 In a clinical trial of breast cancer patients receiving either docetaxel or paclitaxel, patients who completed six cycles of taxane chemotherapy were found to have significant improvement in the cytotoxic immune response as measured by enhanced LAK and NK activity and increased serum levels of GM-CSF, IFN-and IL-2, however serum levels of TNF-and IL-1 decreased. 11 Taxanes are among the most widely used chemotherapy agents for treatment of MBC and have been shown to have considerable activity in the metastatic setting, especially in patients who have received an anthracycline in the adjuvant setting. 35 A disadvantage to incorporating a taxane in a chemoimmunotherapy regimen is the requirement for steroid pre-medication to prevent hypersensitivity reactions. It could be assumed that the weekly doses of dexamethasone used for pre-medication may adversely affect the development of antitumor immunity. A new formulation of paclitaxel, Abraxane™ (paclitaxel protein-bound particles for injectable suspension (albumin-bound)) avoids the need for steroid pre-medication at each chemotherapy dose; an important property when one of the primary goals of the regimen is to enhance the immune response against the tumor. Additionally, in phase III studies, Abraxane demonstrated greater efficacy and a favorable safety profile compared to standard paclitaxel in patients with MBC. 36 Thus, the combination of immunostimulatory properties, improved therapeutic index and elimination of steroid premedication make this novel albumin-bound taxane an important component of chemoimmunotherapy for the treatment of breast cancer cutaneous metastases.
D. Rationale
In this phase II study, chemoimmunotherapy with topical imiquimod and Abraxane will be used in combination for the treatment of cutaneous breast cancer metastases. Rationale behind this approach is three-fold. First, the majority of breast cancer patients with cutaneous metastases have concomitant visceral disease at presentation, usually involving lung and liver. 37, 38 Moreover, prognosis for breast cancer patients with both skin and visceral metastases is poor with reported median survival being only 12 months. 37, 38 Secondly, the safety and efficacy of weekly single-agent Abraxane in patients with metastatic breast cancer, who have been heavily pretreated with taxanes have been well characterized in a recent Phase II study. 39 Response rates in patients treated with Abraxane 100mg/m 2 (n=106) on days 1, 8, and 15 of a 28-day cycle were 14% PR and 12% SD and a median progression-free survival of 3 months. No severe hypersensitivity reactions were reported and Grade 4 neutropenia occurred in less than 5% of patients. Thus, single-agent Abraxane given weekly demonstrates a favorable safety profile and anti-tumor activity in heavily pretreated taxane refractory patients albeit response rates were low and without reported CRs. Lastly, cutaneous metastatic breast cancer is associated with considerable morbidity and in one study was found to be the most negative quality of life (QOL) factor among breast cancer patients. 40 This is attributed to the constant visibility of the skin lesions and associated psychological stress which most likely have a negative impact on a patient's QOL. Imiquimod has demonstrated anti-tumor activity in a variety of skin cancers including mammary Paget's disease and breast cancer cutaneous metastases.
7,33
By using a novel multimodality treatment such as topical imiquimod and Abraxane we will be able to incorporate both local and systemic strategies which are potentially synergistic; and more effective in combination than as single-agents in treating and controlling cutaneous disease with or without visceral metastases. Additionally, the use of weekly Abraxane (days 1, 8, and 15 of a 28-day cycle) will allow us to account for the taxane effect since its efficacy has been well described as noted above. However, while imiquimod and Abraxane have been shown to be safe as single-agent therapies in advanced cancer, the toxicity of this novel combination has not been well defined and warrants further investigation. This study will allow us to better define the safety and anti-tumor effects of this combination treatment in advanced breast cancer patients. Additionally, we will collect data on the immunomodulatory effects of this regimen on the tumor microenvironment and systemic adaptive immunity. FDA approved indications for the use of imiquimod include treatment of external anogenital and perianal warts and actinic keratosis. More recently, off-label applications of imiquimod include clinical trials in BCC, invasive squamous cell carcinoma, lentigo maligna, metastatic melanoma, mycosis fungoides, and more recently, case reports in mammary Paget's disease and advanced refractory breast cancer.
Objectives of Study
7,33 Application-site reactions are commonly seen in patients undergoing topical imiquimod treatment. In most studies, the localized skin reactions were mild to moderate, and the severity is increased in a dose-dependent manner. The most frequently reported application-site reactions include pruritis, erythema, edema and discharge, papular rash, pain, tenderness, and occasionally hypopigmentation or hyperpigmentation. More severe localized reactions such as bleeding, crusting, and erosions occur more often in patients receiving more intensive regimens, e.g. twice daily dosing. A dose-related severity of local reactions was shown in a phase II study assessing the efficacy of various dosing regimens on clearance of superficial BCC lesions (sBCC). 41 In this study, rest periods were required by all patients applying imiquimod twice daily. However, only 50% patients on a once-daily regimen and 25% of patients on a three-times-weekly regimen required rest periods. In most clinical trials, dosing regimens designed to minimize untoward side effects resulted in improved patient compliance and relatively higher therapeutic response rates compared to more intensive regimens. For this reason, this current protocol will use a single daily dosing regimen.
Aldara (imiquimod) Cream, 5%, is supplied in single-use packets which contain 250 mg of the cream which is equivalent to 12.5 mg of imiquimod, and is available in a box of 12 packets (NDC 0089-0610-12). It can be stored at room temperature or refrigerated between 39-77 degrees F (4-25 degrees C). Freezing should be avoided. The Investigational Drug Pharmacy at the University of Washington Medical Center (UWMC) will dispense the drug for administration according to their standard operating procedures.
B. Abraxane
TM (paclitaxel protein-bound particles for injectable suspension (albumin bound)): Abraxane TM is a CremophorEL-free, nanoparticle form of paclitaxel. Abraxane is the first in its class of a biologically interactive nanoparticle combining a protein with a chemotherapeutic agent in the nanoparticle state. This composition provides a novel approach of increasing intra-tumoral concentration of the drug by a receptor-mediated transport process allowing transcytosis across the endothelial cell wall, thereby breaching the blood/tumor interface. Preclinical studies comparing Abraxane to taxol demonstrated lower toxicities, with an MTD approximately 50% higher for Abraxane compared to Taxol. At equal doses there was less myelosuppression and improved efficacy in a xenograft tumor model of human mammary adenocarcinoma. 42 In phase I studies, the MTD of Abraxane was determined to be 300 mg/m 2 by 30 minute infusion every 3 weeks, without premedication or G-CSF support. 43 Two multicenter phase II studies have evaluated 2 dose levels of Abraxane, 175 mg/m 2 (n=43) and 300 mg/m 2 (n=63) in patients with MBC. 1, 44 The overall response rates in these two phase II trials were 40% and 48%, respectively. Of 39 patients receiving 300 mg/m 2 as first-line therapy for MBC, 64% responded. This was contrasted with a 45% response rate in similar patients at the lower dose level. Grade 4 neutropenia which was noted in 24% of patients at the higher dose level occurred primarily during the first cycle and resolved rapidly. Weekly Abraxane administered for 3 weeks followed by a 1 week rest in patients with advanced solid tumors has been studied in a phase I trial. 45 The MTDs for heavily and lightly pre-treated patients were 100 and 150 mg/m 2 , respectively. Dose limiting toxicities (DLT) included myelosuppression and peripheral neuropathy. Premedication was not required, and unexpected, non-taxane associated toxicities were not observed. 45 In a Phase II trial in heavily pretreated patients with taxane-refractory MBC, objective antitumor responses occurred in 15% of women treated with Abraxane 100 mg/m2 on this schedule. 46 Recent phase II studies incorporating weekly Abraxane have not shown increased toxicity over previous dosing schemas in which Abraxane is given weekly for 3 weeks followed by 1 week off. A Phase II study of Albumin-bound paclitaxel 100 mg/m2 given weekly demonstrated the same antitumor activity as albumin-bound paclitaxel 125 mg/m2 weekly and a more favorable safety profile in patients with MBC that had progressed with previous taxane therapy. Grade 4 neutropenia occurred in < 5% of patients. 39 Abraxane is supplied in single-use vials as a white-to-yellow, sterile, lyophilized powder. Each single-use 50 mL vial contains paclitaxel (100 mg) and approximately 900 mg human albumin as a stabilizer. Each mL of reconstituted Protocol 6578/131 suspension contains 5 mg paclitaxel. Each vial will be labeled according to regulatory requirements for labeling of investigational products. Unreconstituted Abraxane should be stored at controlled room temperature (20-25C or 68-77F) in its original carton and unopened vials are stable until the date indicated on the package when stored in the original package at this temperature. Because Abraxane is prepared in albumin, specific reconstitution procedures should be followed in order to minimize drug wastage. Aseptically, reconstitute each vial by injecting 20 mL of 0.9% NaCl Injection, USP. Slowly inject the 20 mL of 0.9% NaCl Injection, USP, over a minimum of 1 minute, using the sterile syringe to direct the solution flow onto the inside wall of the vial. Study pharmacists should not inject the 0.9% NaCl Injection, USP, directly onto the lyophilized cake as this will result in foaming. Once the injection is complete, the vial is allowed to sit for a minimum of 5 minutes to ensure proper wetting of the lyophilized cake/powder. The vial is then gently swirled and/or inverted for at least 2 minutes until complete dissolution of any cake/powder occurs. If foaming or clumping occurs, the solution should stand for at least 15 minutes until foam subsides. Note: Unlike conventional paclitaxel formulations, it is not necessary to use glass or polyolefin containers or in-line filters as Abraxane does not contain Cremophor EL or microfibers. It is not a requirement to use filter needles in the preparation of, or in-line filters during the administration of Abraxane. In any event, filters of pore-size less than 15 µm must not be used. Abraxane, will be infused over 30 minutes IV, diluted in 0.9% NaCl Injection, USP, via an infusion control device (pump) using standard IV administration sets.
Reconstituted Abraxane should be used immediately. If not used immediately, the vial of reconstituted Abraxane must be replaced in its original carton to protect it from bright light and be placed in a refrigerator at 2-8C (36-46F) for a maximum of 8 hours. Neither freezing nor refrigeration adversely affects the stability of the product. Some settling of the reconstituted suspension may occur. Ensure complete resuspension by mild agitation before use. Discard the reconstituted suspension if precipitates are observed. The suspension for infusion prepared as recommended in an infusion bag is stable at ambient temperature (approximately 25ºC or 77ºF) and lighting conditions for up to 8 hours. The UWMC Investigational Drug Pharmacy will dispense Abraxane for administration according to their standard operating procedures. Figure 1 . Thus, 28 days will be defined as 1 treatment cycle and each patient will receive a maximum of 3 treatment cycles. The total treatment period will last 12 weeks followed by 3 follow-up visits at 4-week intervals. The duration of the trial is 24 weeks. 
Eligibility Criteria
B. Sample size
Fifteen patients will be enrolled onto the study. An additional 5 patients may be enrolled to replace study patients who withdraw from study prior to completing the treatment part of the protocol for reasons other than adverse events, e.g. progressive disease, inconvenience. This will provide adequate numbers of subjects for gathering safety and treatment response data as described in Sections 11 and 13, respectively.
C. Outcome measures
The antitumor activity of imiquimod will be assessed using modified WHO criteria and tumor assessment will be done at baseline and then at 4 week intervals until week 24. All measurable cutaneous lesions will be recorded and measured at baseline and the target treatment area selected, accordingly. Tumor responses will be determined using the sum of the products of the largest perpendicular dimensions. Lesion(s) within the target treatment area will be evaluated by the following response criteria: Complete response (CR), Partial response (PR), Stable disease (SD), or Progressive disease (PD). Photodocumentation of response will be performed at each assessment. Additionally, 2-mm skin punch biopsy will be taken from target lesions pre-and post-treatment for assessment of pathologic response Safety and systemic toxicity will be determined by chemical and clinical parameters evaluated at various time points as described in Section 7. Toxicity grading will be evaluated according to the CTEP CTCAE v3.0 and monitoring of adverse events will be done per FDA and NCI guidelines. All adverse events will be tabulated according to the affected body system per CTEP CTCAE v3.0.
Endogenous immunity to common breast tumor antigens (HER2, IGFBP-2, Topoisomerase II-, and p53) will be evaluated using IFN-ELISPOT assay. Peripheral blood will be obtained at baseline, after treatment cycle 3 (1 week following end of study treatment), and at week 24 (end of study) to assess the immune response by ELISPOT. The change in T cell frequencies from baseline for each antigen at each time point will be summarized and described. In patients without pre-existent immune response, the acquisition of a positive immune response (PBMC precursor frequency > 1:20,000) after treatment begins will constitute augmentation. In patients with pre-existent immune response to the tumor antigens, augmentation will have occurred, if the final response to tumor antigen is greater than 2 times the baseline level.
Sera will be obtained at baseline, after treatment cycle 3 (1 week following end of study treatment), and at week 24 (end of study) to evaluate circulating TGF-levels. Analysis of serum will be performed by ELISA. A decrease in serum TGF-levels will be defined as a reduction of at least β5% from baseline value to the value measured at week 13. The treatment period will last 12 weeks followed by a 12-week follow-up period. Patients whose lesions clear prior to the completion of the 12 week treatment period may end application of study drug at the discretion of the investigator. 2. Patients will be instructed to apply imiquimod for a total of 12 weeks as follows: a. Imiquimod, 5% cream is to be applied once per day to the target lesions (within the designated target treatment area), prior to normal sleeping hours, and left on the skin for approximately 8 hours. b. Before applying the cream, the treatment area should be washed with mild soap and water and allowed to dry thoroughly. c. Sufficient cream (1 single-use packet) should be applied to cover the treatment area, including 1 cm of skin surrounding the tumor. The cream should be rubbed into the treatment area until the cream is no longer visible. Following the treatment period of 8-12 hours (generally overnight); cream should be removed by washing the area with mild soap and water. 3. Patients will contact study physician if they experience any sign or symptom in the treatment area that restricts or prohibits their daily activity or makes continued application of the cream difficult. Patients may be evaluated at the investigator's discretion for management of adverse events.
C. Abraxane administration (Days 1, 8, and 15 (+/-2 days) of each 28 day cycle)
1. The first day of Abraxane infusion will be defined as day 1 for each cycle. A clinical evaluation will be done prior to start of each Abraxane infusion and will include weight, vital signs, toxicity/symptom assessment and weekly CBC. A total of 9 weekly doses will be given over a 12 week treatment period (i.e., Abraxane 1-12) 1. Tumor assessment will be performed at baseline prior to start of cycle 1 and after cycles 1, 2, and 3. This will include measurement and photo documentation of the lesion(s) within the target treatment area. 2. A complete history and physical will be performed on Day 1 of cycles 1, 2, and 3 to assess systemic toxicity of the treatment. 3. 10 ml blood will be drawn at day 5 of cycle 1 for global mRNA expression. 4. A 2mm skin punch biopsy of target lesion(s) on day 5 of cycle 1 for microarray analysis. 13, 16, 20, and 24) 1. Clinical evaluation will be performed 1, 4, 8, and 12 weeks after the last treatment cycle of imiquimod/Abraxane (weeks 13, 16, 20, and 24, respectively). The evaluation includes an interim history, physical exam, toxicity/symptom assessment, clinical labs (CBC and CMP) and PS. 2. Tumor assessment will be performed 1, 4, 8, and 12 weeks after the last treatment cycle of imiquimod/Abraxane (weeks 13, 16, 20, and 24, respectively). This will include measurement and photo documentation of the lesion(s) within the target treatment area. 3. A 2mm skin biopsy for IHC will be done on week 13 for evaluation of pathologic treatment response. 4. Blood draw will be performed one week after the last treatment cycle and 12 weeks after the last treatment cycle (week 24) for immunologic analysis as follows: a. 10 ml blood draw (Red top sera tube). b. 110 ml blood draw (heparinized tubes). c. 10 ml blood for global mRNA expression on week 13 only.
D. Other assessments during treatment period (Weeks
E. Follow-up evaluation (Weeks
5. CT imaging of other sites of metastatic disease as per standard of care.
Evaluation of Safety
Clinical status of patients will be evaluated at the first study visit and will include medical history, physical exam, review of systems, performance status and clinical labs (CBC and CMP). These clinical parameters will also be assessed at scheduled follow-up visits on weeks 5 and 9 during the imiquimod/Abraxane treatment period as well as at weeks 13, 16, 20 and 24. Additionally, CBCs will be done prior to each Abraxane dose. Toxicity assessment will be performed at each visit at the time Abraxane is administered and at scheduled follow-up visits on weeks 13, 16, 20, and 24. Toxicity grading will be evaluated according to the CTEP CTCAE v3.0 and monitoring of adverse events will be done per FDA and NCI guidelines as described in the Data and Safety Monitoring Plan in Appendix B. A copy of the CTEP CTCAE v3.0 can be down loaded from the CTEP home page (http://ctep.cancer.gov). Safety precautions during infusion of Abraxane include monitoring vital signs and administration of ondansetron (or granisetron) for anti-emetic prophylaxis. Additionally, patients may be evaluated more frequently at the investigator's discretion for management of adverse events. Patients with drug related toxicity will be followed until resolution or stabilization of the toxicity.
Dose Modifications and Treatment Delay
Dosage modifications are described below. Dose adjustments will be made according to the system showing the greatest degree of toxicity per CTEP CTCAE v3.0. For any event present at baseline, the dose modification will apply according to the corresponding shift in toxicity grade if the investigator feels it is appropriate (e.g. if a patient has a grade 1 asthenia at baseline which increases to grade 2 during treatment, this will be considered a shift of 1 grade and treated as a grade 1 toxicity for dose modification purposes). If the investigator considers it unlikely that a given toxicity will develop into a serious or life-threatening event (e.g. alopecia, altered taste, etc.), treatment will be continued at the same dose without reduction or interruption. In addition, no dose reductions or interruptions will be required for anemia as it can be satisfactorily managed by transfusions or erythropoetin growth factors as per standard of care. Additional considerations for dose reductions and treatment delays include: (1) Dose reductions for hematological or non-hematological toxicities will be permanent reductions, (2) If Abraxane and/or imiquimod treatment is withheld during treatment cycles for any reason other than toxicity, doses will be made up (i.e., patient should receive a total of 3 treatment cycles if possible), and (3) Patients who are off treatment for more than 21 days for any reason will be considered off study treatment.
A. Imiquimod
All patients will be maintained at the constant dose of imiquimod 5% cream (1 single-use packet) to be applied topically to the designated target area once a day for 4 consecutive days on Days 1-4, 8-11, 15-18, and 22-25 of a 28 Day cycle, for a total of 12 weeks of treatment. However, as local skin reactions are common and expected, a rest period may be taken if required by the patients discomfort or severity of local skin reaction (see Section 10 below).
B. Abraxane
All patients will be maintained at the constant dose level of 100 mg/m 2 throughout the study for a total of 9 weekly doses over a 12 week period however, dose reductions will be instituted for toxicity as described below. Dose reductions will be made according to the system showing the greatest degree of toxicity. Abraxane dose reduction levels are shown in Table 2 . Dose reductions for toxicity will be based on laboratory values and clinical evaluation obtained on day 1 of each treatment cycle as described below. 1. Abnormal hematologic function CBC will be checked weekly prior to Abraxane dosing. The following CBC parameters should be used when Abraxane is first initiated: WBC ≥ γ000/ul, ANC ≥ 1β00/ul and platelets >100,000/ul. For each subsequent weekly dose of Abraxane, patients must have an ANC ≥ 1000/ul and platelets ≥ 75,000/ul. If the ANC and platelets are not adequate for treatment, Abraxane is to be held on a week-by-week basis until ANC and platelets recover to these parameters. G-CSF may be given as clinically indicated. If Abraxane is delayed due to neutropenia, institute G-CSF 5 mcg/kg/day subcutaneous. G-CSF will be started the day after Abraxane is given and stopped at least 24 hours prior to the next weekly Abraxane dose (i.e., Abraxane on Day 1 and G-CSF on Days 2-5). Guidelines for implementing dose reductions and G-CSF for hematologic toxicity are shown in Table 3 below. At the 1st occurrence of neutropenia the same dose is maintained and G-CSF is given as outlined below. In the event that neutropenia re-occurs in the face of G-CSF, dose reduction to the next lower level will be required for subsequent cycles once ANC is ≥ 1000 cells/mm
If G-CSF is given with weekly Abraxane, administration will begin the day after Abraxane is given and should stop at least 24 hours prior to when Abraxane is given the following week.
Thrombocytopenia
Grade 3 or Grade 4* 2. Abnormal liver function Abraxane may be administered if hepatic function is outside the parameters established in the eligibility criteria per treating physician discretion, following standard clinical practice. Hepatic toxicity from taxanes may occur but it is uncommon. Hepatic dysfunction that occurs while the patient is on study should prompt an evaluation to determine the cause, including the possibility of progressive metastatic disease and hepatotoxicity from concurrent medications.
3. Peripheral neuropathy Abraxane should be withheld in patients who experience ≥ Grade γ peripheral neuropathy. Treatment may be resumed at the next lower dose level (see Table 2 ) in subsequent cycles after the peripheral neuropathy improves to ≤ Grade 1. The time to resolution to Grade ≤ 1 should be the AE duration used for AE reporting. In those patients who experience Grade 4 peripheral neuropathy, Abraxane should be withheld, and treatment resumed at a reduction of 2 dose levels (Dose Level -β; see Table β ) in subsequent cycles after the peripheral neuropathy improves to ≤ Grade 1.
Gastrointestinal toxicity
If ≥ grade γ mucositis occurs, Abraxane should be withheld until resolution to ≤ grade 1, then reinstituted at the next lower dose level (see Table 2 ).
Hypersensitivity reactions
Hypersensitivity reactions are not expected with Abraxane. If they do occur, minor symptoms such as flushing, skin reactions, dyspnea, hypotension, or tachycardia may require temporary interruption of the infusion. However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema or generalized urticaria require immediate discontinuation of Abraxane administration and aggressive symptomatic therapy. Patients who develop severe hypersensitivity reactions to Abraxane may be re-challenged following pre-medication that the institution would typically use for paclitaxel.
Cutaneous toxicity
Patients who develop severe or cumulative cutaneous toxicity should have their dose reduced by 1 dose level. If the patient continues to experience these reactions, the dosage should be reduced to the next lower dose level.
Other Toxicities
If toxicities are ≤ grade β, manage symptomatically if possible, and retreat without dose reduction. If toxicities are ≥ grade 3, and/or except for anemia, treatment should be withheld until resolution to ≤ grade 1 or baseline if baseline was greater than grade 1, then reinstituted, if medically appropriate, at the next lower dose level (see Table 2 ).
Management of Toxicities and Complications
Abraxane is administered at 100 mg/m 2 over 30 minutes on Days 1, 8, and 15 +/-2 days of every 28 Day cycle for 3 cycles. Patients do not require premedication for prophylaxis of hypersensitivity prior to Abraxane infusion, as hypersensitivity reactions are not expected. In the unlikely event of a hypersensitivity reaction, pre-medication may be administered using the pre-medication regimen the institution typically uses for paclitaxel (also see package insert). G-CSF will be used as clinically indicated per parameters described in Section 9.B. and Table 3 .
Topical imiquimod administration has been extensively tested and application-site skin reactions are commonly seen in patients undergoing treatment. In most studies, the localized skin reactions were mild to moderate, and the severity is increased in a dose-dependent manner. The most frequently reported application-site reactions include pruritis, erythema, edema and discharge, papular rash, pain, tenderness, and occasionally hypo-or hyperpigmentation. More severe localized reactions such as bleeding, crusting, erosions, and indurations occur more often in patients on more intensive regimens (i.e., twice daily dosing or once-a-day dosing 7 days/week). In phase II studies, rest periods of up to 7 days were allowed for patients with severe localized reactions and did not impact efficacy and serious adverse events were minimized. 29 Thus, if grade 3 or higher cutaneous toxicity is observed at the application-site, a rest period will be allowed until there is resolution of toxicity to ≤ grade β or baseline. Imiquimod will then be restarted at the same dose. Additionally, imiquimod will not be applied to open ulcerative lesions.
Criteria for Premature Study Termination
Accrual to the study will be terminated if excessive treatment-related toxicity is observed. Stopping rules will become operational if there is sufficient evidence that the true incidence of treatment-related unexpected Grade 3 or higher toxicity Protocol 6578/131 exceeds 40%, including an upper limit of 20% incidence of Grade 4 toxicity. The toxicity rates will be evaluated after every fifth enrolled patient becomes evaluable, and sufficient evidence will be defined as observed rates of toxicity that correspond to one-sided 80% confidence intervals with lower limits greater than 40% (Grade 3 or higher) or 20% (Grade 4). Operationally, these limits would be achieved if 4/5, 6/10, or 9/15 patients experienced Grade 3 or higher toxicity, or if 3/5, 4/10, or 5/15 patients experienced Grade 4 toxicity. Tables 4 and 5 summarize the operating characteristics of these stopping rules, where the probability of stopping the study is estimated from 5,000 Monte Carlo simulations.
Grade 3 toxicity including anemia, leukopenia, lymphopenia, neutropenia, thrombocytopenia, peripheral neuropathy, mucositis, and cutaneous toxicity are expected adverse events with Abraxane and/or imiquimod treatment. As such, parameters for management of these expected toxicities and subsequent dose modifications/treatment delays (per the manufacture's brochure) are defined in Section 9 and Section 10; and these Grade 3 toxicities will not activate the stopping rules above. 
A. Additional considerations for early termination of therapy prior to completion of study.
In addition to the above criteria the following patients will be removed from study: (1) Patients with any toxicity resulting in a treatment delay of more than 21 days, and (2) Patients with clinically significant progressive symptoms and/or radiographic evidence of increased disease requiring conventional medical treatment.
Evaluation of Clinical Efficacy
A. Tumor assessment Anti-tumor activity will be assessed using modified WHO criteria. Patients will have a tumor evaluation at baseline, weeks 5, 9, 13, 16, 20, and 24. Tumor evaluation done at weeks 5, 9, 13, 16, 20 and 24 will be compared to baseline for the purpose of evaluating response to imiquimod and Abraxane treatment. Patients who discontinue treatment prematurely will have their end-of-treatment procedures done 1 week following their final dose of imiquimod. Local tumor response will be assessed by clinical examination including tumor measurement and photodocumentation.
B. Documentation of lesions within and outside the target treatment area
All measurable cutaneous metastases will be recorded and measured at baseline and the target treatment area selected, accordingly. The selected treatment area will be marked using indelible ink marker and a customizable 100 cm 2 template. All tumor lesions within the defined target treatment area will be considered as one lesion for measurement and evaluation purposes. The location within the defined treatment area that has the largest tumor mass will be identified and marked using a small tattoo in order to ensure biopsies are taken from the same local area. A surrounding area of 1cm from the lesion border(s) should also be identified on the template. The occurrence of cutaneous lesions outside the treatment area (non-treated/non-targeted lesions) and/or the development/progression of systemic disease will be recorded and followed according to good clinical practices. The objective of lesion assessment is to provide a systematic and objective approach to identify and measure lesions so that assessments can be done consistently throughout the entire trial period.
C. Photographs of lesions
Photographs of the metastatic cutaneous lesions will be obtained at baseline before initial biopsy and at 4 week intervals during the study at the time of tumor assessement. Standardized identifiers will be applied with a sticker (date, unique patient ID number, initials, cm-scale) in place. These photographs will assist in monitoring the dynamics of the lesions and local skin adverse reactions occurring within the treated area(s). At each subsequent visit, these aforementioned areas should be photographed even if the lesion(s) within the target treatment area have resolved. Photographic documentation may also be used to document toxicity.
D. Measurement of lesion area
The investigator will provide bi-dimensional measurements consisting of the longest dimension and the widest dimension (perpendicular to the longest dimension) in centimeters. A target lesion template will be created for each patient using a permanent marker on a clear plastic overlay to map the target lesion itself. 1-2 small tattoo marks may also be placed at the site of the tumor lesion to aid in locating the site of the initial tumor biopsy and ensure the post treatment biopsy is taken from an adjacent location. The treated target lesion will be measured at baseline (prior to start of imiquimod/Abraxane treatment) and then at weeks 5, 9, 13, 16, 20 and 24. Tumor responses will be determined using the sum of the products of the largest perpendicular dimensions. Non-measurable lesions including skin lesions too small to be reliably measured (< 0.5 cm) or soft tissue metastases will also be identified by the investigator at baseline and after the treatment. Measurement of these lesions will not be required but the lesion status using the following categories should be noted: increased, decreased, stable, resolved, or not assessed. Lesions that are unable to be measured (UTM) due to local skin adverse reactions will be clearly described in the CRF. The last observation carried forward (LOCF) should be used in this case to calculate the surface area.
E. Evaluation of lesions within the target treatment area
Anti-tumor activity of imiquimod will be assessed using modified WHO criteria. Lesion(s) within the target treatment area will be evaluated by the following response criteria: (1 
Statistical Considerations A. Study statistics
This is a phase II study designed to evaluate the safety, anti-tumor effects, and immune effects of imiquimod and Abraxane in patients with cutaneous metastatic breast cancer. The primary objectives are to evaluate the safety and clinical efficacy of treatment with imiquimod in combination with Abraxane. Clinical efficacy will be evaluated primarily based on response rate, although other measures of efficacy will be assessed as described below.
Anti-tumor effects of imiquimod will be determined by evaluating tumor response per modified WHO criteria. All measurable cutaneous lesions will be recorded and measured at baseline, and target lesions in the target treatment area selected accordingly. Target lesions will be evaluated by the following response criteria: (1) Complete response (CR)-complete clearance (100%) of target lesions, (2) Partial response (PR)-≥ 50% decrease in size of target lesions, (γ) Stable disease (SD)-< 50% decrease in size of target lesions, (4) Progressive disease (PD)-increase in ≥ β5% of the target lesions.
Fifteen patients will be enrolled to study as described in Section 6.B. This sample size is not derived based on statistical considerations, but rather on a balance between a number of patients that we feel can be accrued in a reasonable time frame and a number that will provide us with some meaningful data that will help us determine whether to study the proposed treatment further. Historical overall response rates (ORR) with second-and third-line salvage chemotherapy range from 20-30%, with CR rates less than 2%. Based on these numbers, the current study will use an ORR of 50% or a CR rate of 10% as benchmarks for success. If we see 8 or more responses or 2 or more CRs among the 15 patients (for an observed ORR of ≥ 53% or an observed CR rate of ≥ 13%), we will consider the treatment to be worthy of further study. If such an event occurs, we will consider conducting a larger phase II study with the goal of showing that the response rate associated with this treatment is statistically significantly better than second-and third-line salvage chemotherapy. Summarized in Tables 6 and 7 are probabilities of "success" as defined above for various assumed-true response rates. As a measure of the precision of the estimate of overall response rate achievable with 15 patients, if the response rate is 60%, we will be 80% confident that the observed response rate is within 0.16 of the true response rate with 15 patients treated. Safety and systemic toxicity will be determined by chemical and clinical parameters evaluated at various time points as described in Section 7. The type and grade of toxicities noted during treatment will be summarized. All adverse events noted by the investigator will be tabulated according to the affected body system.
A variety of endpoints will be evaluated at various time points as described in Section 7. Changes from baseline for each of these will be calculated, and a statistical test of the null hypothesis that the change from baseline is zero will be conducted using the one-sample t-test. If the true effect size for a particular parameter (defined as the change from baseline divided by the standard deviation of change) is 0.8, then 15 patients will provide 90% power to observe a statistically significantly change from zero at the one-sided significance level of 0.05; a true effect size of 0.7 yields 82% power. This consideration applies to the immunologic endpoints, ELISPOT and TGF-levels.
Endogenous immunity to common breast tumor antigens (HER2, IGFBP-2, Topoisomerase II-, and p53) will be evaluated using IFN-ELISPOT assay. Peripheral blood will be obtained at baseline, after cycle 3 (end of study treatment) and at week 24 (end of study) to assess the immune response. A positive antigen-specific T cell immune response will be defined as a T cell precursor frequency more robust than 1:20,000 PBMC if the patients did not have a detectable response prior to treatment. The change in T cell frequencies from baseline for each antigen at each time point will be summarized and described. In patients with a pre-existent immune response, the development of an immune response twice baseline will constitute augmentation.
Finally, serial serum levels of TGF-will be assessed with ELISA at baseline, after cycle 3 (1 week following end of treatment), and at week 24 (end of study) to determine the incidence of reduction of TGF-in patients during chemoimmunotherapy; and explore whether such reductions are associated with generation of Th1 adaptive immunity as well as clinical response. A decrease in serum TGF-levels will be defined as a reduction of at least β5% from baseline value to the value measured at week 13.
B. Projected gender and ethnic distribution
The ethnic and gender distribution table below reflects estimates of race and gender of the study population. These estimates are based on the following general statistics of the population in the Pacific Northwest as well as the characteristics of the disease to be studied. The population pool from which we will be drawing our study group is 75% Caucasian, 15% Asian American, and 10% African American. The number of Hispanic, Native Hawaiian (or other Pacific Islander) or American Indian (or Native Alaskan) patients available for study is unknown at this time. Fifteen patients be enrolled as described in Section 6.B. Although men are not excluded from this study, breast cancer occurs primarily in women and predominantly in the sixth decade. Thus, Table 8 represents primarily a female population and an estimate of the ethnicity of patients who will potentially be enrolled on this study. 14. Administrative Considerations A. Specimen handling Upon entry into the study each patient will be assigned a unique identification number. All materials collected on that patient will be labeled with that number only for reasons of confidentiality.
B. Institutional Review Board
In accordance with federal regulations (21 CFR 312.66), an Institutional Review Board (IRB) that complies with the regulations in 21 CFR 56 must review and approve this protocol and the informed consent form prior to the initiation of the study.
C. Consent
The Principal Investigators or their associates must explain verbally and in writing the nature, duration, and purpose of the study and possible consequences of the treatment. Patients must also be informed that they may withdraw from the study at any time and for any reason without jeopardizing their future treatment. In accordance with Federal regulations (21 CFR 312), all patients must sign the IRB approved consent form prior to undergoing any study related procedures. 5. Adverse event reporting is outlined below and in Table 1 by regulatory agency. a. FHCRC -Cancer Consortium IRB -We will follow current IRB policies for reporting AE's and unexpected events. b. UW Clinical Research Center (CRC) -We will report AE and serious AE to the CRC in the same manner as the IRB. c. FDA for trials using an Investigational New Drug (IND) -This study does not require an IND. 6. Procedure for reporting adverse events: a. Identify the classification/attribution of the AE as defined above using the CTEP CTCAE v3.0. b. After appropriate medical intervention has been instituted, the P.I. or designee will be notified within 24 hours. c. File appropriate reports immediately by phone/fax with appropriate agencies, as described above. d. Notify the subject's primary physician or referring physician within a medically appropriate timeframe, depending on the classification of the AE. e. Submit written reports to appropriate agencies. f. Document the AE in the subject's chart, using a progress note to describe the event and treatment, if appropriate. g. File copies of all forms/correspondence relating to the AE in the subject's chart. (Table 2) 1. Clinical Data Documentation a. Dosing Cycle Monitoring: All subjects actively enrolled in the study are treated for 12 weeks and followed for 12 weeks after the last treatment. Clinical laboratory monitoring data is reviewed in real time by the P.I., Research M.D., or Physician's Assistant (PA)/Nurse Practitioner (NP) and any abnormalities are assessed and noted in the chart. This document becomes part of the patient chart at the end of the study. Any clinically significant abnormal lab values are faxed to the subject's physician and followed with a letter. The P.I., Research M.D., PA or NP sees each study participant for each treatment week and the following evaluations may be completed: toxicity evaluation, brief physical assessment and AE summary (these evaluations are part of the source document that is filled out at each visit). Grade 1 and 2 non-serious and expected AE will be reviewed with the P.I. at regular meetings. All other AE will be reported to the P.I. at the time they become known and reported according to the schedule outlined above in Section C.
D. Clinical Trials Monitoring Operational Procedures
Each subject chart is audited for completeness at the end of each subject visit. In addition, the chart is audited by the Research Nurse, Research Coordinator or other clinical research staff member at the initial evaluation, treatment weeks 1, 5, 9 and 12 and follow-up after treatment weeks 4, 8 and 12. The results will regularly be presented to the P.I.. Charts are audited for completeness, legibility, and accuracy. All source documents must be filled out completely. The Research Nurse, Research Coordinator or other clinical research staff member will review all charts for subject recruitment and retention, protocol adherence, follow-up, data quality, and participant risk versus benefit. Additionally, all correspondence with primary physicians and subject is maintained in the subject chart.
b. Biannual Monitoring Visit: An Independent Study Monitor will be assigned by the FHCRC -Cancer Consortium IRB CTSO and they will perform an independent study audit twice a year (approximately every 6 months) when subjects have been enrolled. This audit will be conducted on a sampling of subjects who have been enrolled on study at the time of the monitoring visit. Charts will be formally audited for completeness, accuracy and compliance to protocol.
Data validity/integrity
Systems to insure data integrity have been put into place to provide multiple checks to data entry.
Subject eligibility, at a minimum, is reviewed by a Clinical Research Staff Member and by a Research MD prior to enrollment, and biannually by the Study Monitor. The study P.I. makes the final assessment regarding eligibility and is responsible for resolving any outstanding issues. It is at this time the patient is scheduled for an initial appointment.
All toxicity scoring is reviewed with the P.I. and at the end of study, toxicity scoring is tabulated by a Clinical Research Staff Member and reviewed with the P.I. All research data and immunologic monitoring is reviewed by the P.I. and discussed with the laboratory technologist (Lab Tech) or post-doctoral fellow who generated the data.
Data is taken from the subject's case report forms (also the source document for each subject) and entered into a database which links data to subject by a Unique Patient Identifier Number and is accessible by password code only. Data entry is made by a Clinical Research Staff Member and is verified throughout the study by a Clinical Research Staff Member by reviewing all source documents and reconciling them to the study database. 10% of all data entry is reviewed by the Independent Study Monitor at review. At the time of study reports or publications, print-outs of all data from the data base are reviewed by the P.I. 
